[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The la

Investors need to pay close attention to ATRC stock based on the movements in the options market lat

AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc

[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

AtriCure NASDAQ: ATRC executives said the company's 2026 revenue outlook is being supported by recen

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises

AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the q

AtriCure (ATRC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate

2026 Financial GuidanceFull year 2026 revenue is projected to be approximately $600 million to $610

AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.00 per share which beat the analyst consens

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center c

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

ArtiCure Chief Science Officer sold 5,000 shares for a transaction value of approximately $149,000 a

Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have earned a consensus rating of "Moderat

Citigroup Inc. raised its position in AtriCure, Inc. (NASDAQ: ATRC) by 182.0% in the undefined quart

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

AtriCure (NASDAQ: ATRC) reported fourth-quarter and full-year 2025 results that management said refl

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers

UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price ta

Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and low

AtriCure (NASDAQ:ATRC) is looking for FY2026 Adj EPS of $0.09-$0.15 vs $(0.04) analyst estimate. Aff

AtriCure (NASDAQ:ATRC) affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.0

AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.06 per share which beat the analyst consens

2026 Financial GuidanceManagement projects 2026 revenue of approximately $600 million to $610 millio

AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fi

JP Morgan analyst Lilia-Celine Lozada maintains AtriCure (NASDAQ:ATRC) with a Overweight and rais

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises

AtriCure (NASDAQ:ATRC) raises FY2025 Adj EPS guidance from $(0.39)-$(0.34) to $(0.26)-$(0.23) vs $(0

AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.01) per share which beat the analyst consens

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial f

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price targ

AtriCure (NASDAQ:ATRC) raises FY2025 Adj EPS guidance from $(0.55)-$(0.50) to $(0.39)-$(0.34) vs $(0

AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.02) per share which beat the analyst consens